SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

BACKGROUND: In preclinical Ewing sarcoma (ES) models, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with synergy in combination with cytotoxic agents. This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer
Main Authors: Chugh, Rashmi, Ballman, Karla V., Helman, Lee J., Patel, Shreyaskumar, Whelan, Jeremy S., Widemann, Brigitte, Lu, Yao, Hawkins, Douglas S., Mascarenhas, Leo, Glod, John W., Ji, Jiuping, Zhang, Yiping, Reinke, Denise, Strauss, Sandra J.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246769/
https://ncbi.nlm.nih.gov/pubmed/33289920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33349
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki